{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:37:44Z","timestamp":1792715864493,"version":"4.5.0"},"reference-count":112,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T00:00:00Z","timestamp":1783382400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.esmoop.2026.108349","type":"journal-article","created":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T10:16:11Z","timestamp":1788948971000},"page":"108349","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Liquid biopsy: a new window on the BRCA genes"],"prefix":"10.1016","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1199-7286","authenticated-orcid":false,"given":"L.","family":"Incorvaia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Gristina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Pepe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-5595-3924","authenticated-orcid":false,"given":"T.D.","family":"Bazan Russo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Santoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-1748-6337","authenticated-orcid":false,"given":"C.","family":"Mujacic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1781-2518","authenticated-orcid":false,"given":"G.","family":"Curigliano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"U.","family":"Malapelle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5647-4059","authenticated-orcid":false,"given":"E.D.","family":"Capoluongo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4370-2008","authenticated-orcid":false,"given":"A.","family":"Russo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.esmoop.2026.108349_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100459","article-title":"Implementation of preventive and predictive BRCA testing in patients with breast, ovarian, pancreatic, and prostate cancer: a position paper of Italian scientific societies","volume":"7","author":"Russo","year":"2022","journal-title":"ESMO Open"},{"issue":"14","key":"10.1016\/j.esmoop.2026.108349_bib2","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1200\/JCO.21.02112","article-title":"Cancer risks associated with BRCA1 and BRCA2 pathogenic variants","volume":"40","author":"Li","year":"2022","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.esmoop.2026.108349_bib3","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1056\/NEJMra1503523","article-title":"The role of risk-reducing surgery in hereditary breast and ovarian cancer","volume":"374","author":"Hartmann","year":"2016","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.esmoop.2026.108349_bib4","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/s41416-019-0446-1","article-title":"International trends in the uptake of cancer risk reduction strategies in women with a BRCA1 or BRCA2 mutation","volume":"121","author":"Metcalfe","year":"2019","journal-title":"Br J Cancer"},{"issue":"10","key":"10.1016\/j.esmoop.2026.108349_bib5","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.6004\/jnccn.2023.0051","article-title":"NCCN Guidelines\u00ae Insights: genetic\/familial high-risk assessment: breast, ovarian, and pancreatic, version 2.2024","volume":"21","author":"Daly","year":"2023","journal-title":"J Natl Compr Canc Netw"},{"issue":"6330","key":"10.1016\/j.esmoop.2026.108349_bib6","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1126\/science.aam7344","article-title":"PARP inhibitors: synthetic lethality in the clinic","volume":"355","author":"Lord","year":"2017","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.esmoop.2026.108349_bib7","doi-asserted-by":"crossref","first-page":"5584","DOI":"10.1038\/s41467-020-19406-4","article-title":"Pan-cancer landscape of homologous recombination deficiency","volume":"11","author":"Nguyen","year":"2020","journal-title":"Nat Commun"},{"issue":"4","key":"10.1016\/j.esmoop.2026.108349_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100235","article-title":"Impact of deleterious variants in other genes beyond BRCA1\/2 detected in breast\/ovarian and pancreatic cancer patients by NGS-based multi-gene panel testing: looking over the hedge","volume":"6","author":"Bono","year":"2021","journal-title":"ESMO Open"},{"key":"10.1016\/j.esmoop.2026.108349_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2023.102650","article-title":"Theranostic biomarkers and PARP-inhibitors effectiveness in patients with non-BRCA associated homologous recombination deficient tumors: still looking through a dirty glass window?","volume":"121","author":"Incorvaia","year":"2023","journal-title":"Cancer Treat Rev"},{"issue":"9","key":"10.1016\/j.esmoop.2026.108349_bib10","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/j.trecan.2024.06.008","article-title":"PARPi, BRCA, and gaps: controversies and future research","volume":"10","author":"Dibitetto","year":"2024","journal-title":"Trends Cancer"},{"issue":"14","key":"10.1016\/j.esmoop.2026.108349_bib11","doi-asserted-by":"crossref","first-page":"2725","DOI":"10.1158\/1078-0432.CCR-22-3715","article-title":"Investigation of PARP inhibitor resistance based on serially collected circulating tumor DNA in patients with BRCA-mutated ovarian cancer","volume":"29","author":"Kim","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"5","key":"10.1016\/j.esmoop.2026.108349_bib12","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/j.annonc.2020.02.008","article-title":"Reversion and non-reversion mechanisms of resistance to PARP inhibitor or platinum chemotherapy in BRCA1\/2-mutant metastatic breast cancer","volume":"31","author":"Waks","year":"2020","journal-title":"Ann Oncol"},{"issue":"9","key":"10.1016\/j.esmoop.2026.108349_bib13","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1007\/s40265-024-02071-y","article-title":"Combination of PARP inhibitors and androgen receptor pathway inhibitors in metastatic castration-resistant prostate cancer","volume":"84","author":"Kostos","year":"2024","journal-title":"Drugs"},{"issue":"9","key":"10.1016\/j.esmoop.2026.108349_bib14","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.3390\/cancers12092415","article-title":"Detection of germline mutations in a cohort of 139 patients with bilateral breast cancer by multi-gene panel testing: impact of pathogenic variants in other genes beyond","volume":"12","author":"Fanale","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"3","key":"10.1016\/j.esmoop.2026.108349_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100144","article-title":"The role of homologous recombination deficiency testing in ovarian cancer and its clinical implications: do we need it?","volume":"6","author":"Ngoi","year":"2021","journal-title":"ESMO Open"},{"issue":"1","key":"10.1016\/j.esmoop.2026.108349_bib16","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1186\/s13046-023-02743-9","article-title":"Network approach in liquidomics landscape","volume":"42","author":"Santini","year":"2023","journal-title":"J Exp Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.esmoop.2026.108349_bib17","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1038\/s41392-024-02021-w","article-title":"Liquid biopsy in cancer current: status, challenges and future prospects","volume":"9","author":"Ma","year":"2024","journal-title":"Signal Transduct Target Ther"},{"issue":"10","key":"10.1016\/j.esmoop.2026.108349_bib18","doi-asserted-by":"crossref","first-page":"2847","DOI":"10.3390\/cancers15102847","article-title":"Practical utility of liquid biopsies for evaluating genomic alterations in castration-resistant prostate cancer","volume":"15","author":"Jeong","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"33","key":"10.1016\/j.esmoop.2026.108349_bib19","doi-asserted-by":"crossref","first-page":"5204","DOI":"10.1038\/s41388-021-01928-w","article-title":"Applicability of liquid biopsies to represent the mutational profile of tumor tissue from different cancer entities","volume":"40","author":"Liebs","year":"2021","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/j.esmoop.2026.108349_bib20","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1038\/s41467-017-00965-y","article-title":"Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors","volume":"8","author":"Adalsteinsson","year":"2017","journal-title":"Nat Commun"},{"issue":"12","key":"10.1016\/j.esmoop.2026.108349_bib21","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djx118","article-title":"Concordance of circulating tumor DNA and matched metastatic tissue biopsy in prostate cancer","volume":"109","author":"Wyatt","year":"2017","journal-title":"J Natl Cancer Inst"},{"issue":"9","key":"10.1016\/j.esmoop.2026.108349_bib22","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1158\/2159-8290.CD-17-0261","article-title":"Circulating cell-free DNA to guide prostate cancer treatment with PARP inhibition","volume":"7","author":"Goodall","year":"2017","journal-title":"Cancer Discov"},{"issue":"1","key":"10.1016\/j.esmoop.2026.108349_bib23","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1158\/1078-0432.CCR-22-0931","article-title":"Detection of BRCA1, BRCA2, and ATM alterations in matched tumor tissue and circulating tumor DNA in patients with prostate cancer screened in PROfound","volume":"29","author":"Chi","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.esmoop.2026.108349_bib24","first-page":"176","article-title":"Circulating tumor DNA in advanced solid tumors: clinical relevance and future directions","volume":"71","author":"Cheng","year":"2021","journal-title":"CA Cancer J Clin"},{"issue":"11","key":"10.1016\/j.esmoop.2026.108349_bib25","doi-asserted-by":"crossref","first-page":"5522","DOI":"10.3390\/ijms22115522","article-title":"Circulating tumor DNA testing for homology recombination repair genes in prostate cancer: from the lab to the clinic","volume":"22","author":"Cimadamore","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"9","key":"10.1016\/j.esmoop.2026.108349_bib26","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1080\/14737159.2019.1657011","article-title":"Detection of BRCA1\/2 large genomic rearrangements in breast and ovarian cancer patients: an overview of the current methods","volume":"19","author":"Concolino","year":"2019","journal-title":"Expert Rev Mol Diagn"},{"issue":"6","key":"10.1016\/j.esmoop.2026.108349_bib27","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1111\/iju.15441","article-title":"Prostate cancer and liquid biopsies: clinical applications and challenges","volume":"31","author":"Urabe","year":"2024","journal-title":"Int J Urol"},{"issue":"60","key":"10.1016\/j.esmoop.2026.108349_bib100","doi-asserted-by":"crossref","first-page":"101325","DOI":"10.18632\/oncotarget.20722","article-title":"Detection of BRCA1\/2 mutations in circulating tumor DNA from patients with ovarian cancer","volume":"8","author":"Ratajska","year":"2017","journal-title":"Oncotarget"},{"issue":"2","key":"10.1016\/j.esmoop.2026.108349_bib29","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1158\/2159-8290.CD-18-0715","article-title":"BRCA reversion mutations in circulating tumor DNA predict primary and acquired resistance to the PARP inhibitor rucaparib in high-grade ovarian carcinoma","volume":"9","author":"Lin","year":"2019","journal-title":"Cancer Discov"},{"issue":"18","key":"10.1016\/j.esmoop.2026.108349_bib30","doi-asserted-by":"crossref","first-page":"3706","DOI":"10.1158\/1078-0432.CCR-23-0797","article-title":"Identifying mechanisms of resistance by circulating tumor DNA in EVOLVE, a phase II trial of cediranib plus olaparib for ovarian cancer at time of PARP inhibitor progression","volume":"29","author":"Lheureux","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"22","key":"10.1016\/j.esmoop.2026.108349_bib31","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1056\/NEJMoa1911440","article-title":"Olaparib for metastatic castration-resistant prostate cancer","volume":"382","author":"de Bono","year":"2020","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.esmoop.2026.108349_bib32","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1093\/annonc\/mdx542","article-title":"Surfaceome profiling enables isolation of cancer-specific exosomal cargo in liquid biopsies from pancreatic cancer patients","volume":"29","author":"Castillo","year":"2018","journal-title":"Ann Oncol"},{"issue":"11","key":"10.1016\/j.esmoop.2026.108349_bib33","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1158\/2159-8290.CD-20-0466","article-title":"Precision prevention and cancer interception: the new challenges of liquid biopsy","volume":"10","author":"Serrano","year":"2020","journal-title":"Cancer Discov"},{"issue":"6","key":"10.1016\/j.esmoop.2026.108349_bib34","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1093\/jnci\/djae060","article-title":"Frameshift mutations in peripheral blood as a biomarker for surveillance of Lynch syndrome","volume":"116","author":"Song","year":"2024","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"10.1016\/j.esmoop.2026.108349_bib35","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/s41698-021-00198-9","article-title":"A DNA methylation-based liquid biopsy for triple-negative breast cancer","volume":"5","author":"Cristall","year":"2021","journal-title":"NPJ Precis Oncol"},{"issue":"18","key":"10.1016\/j.esmoop.2026.108349_bib36","doi-asserted-by":"crossref","first-page":"4852","DOI":"10.1158\/1078-0432.CCR-20-0638","article-title":"Identification of somatically acquired BRCA1\/2 mutations by cfDNA analysis in patients with metastatic breast cancer","volume":"26","author":"Vidula","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"21","key":"10.1016\/j.esmoop.2026.108349_bib37","doi-asserted-by":"crossref","first-page":"6708","DOI":"10.1158\/1078-0432.CCR-17-0544","article-title":"Diverse BRCA1 and BRCA2 reversion mutations in circulating cell-free DNA of therapy-resistant breast or ovarian cancer","volume":"23","author":"Weigelt","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"suppl 7","key":"10.1016\/j.esmoop.2026.108349_bib38","doi-asserted-by":"crossref","first-page":"6094","DOI":"10.1158\/1538-7445.AM2023-6094","article-title":"Abstract 6094: Longitudinal analysis of PARP inhibitor and platinum resistance in BRCA1\/2m breast cancer using liquid biopsy","volume":"83","author":"Harvey-Jones","year":"2023","journal-title":"Cancer Res"},{"issue":"6","key":"10.1016\/j.esmoop.2026.108349_bib39","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1007\/s13277-012-0443-y","article-title":"DNA methylation of circulating DNA: a marker for monitoring efficacy of neoadjuvant chemotherapy in breast cancer patients","volume":"33","author":"Sharma","year":"2012","journal-title":"Tumour Biol"},{"issue":"10","key":"10.1016\/j.esmoop.2026.108349_bib40","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1002\/ijc.30650","article-title":"Analysis of ctDNA to predict prognosis and monitor treatment responses in metastatic pancreatic cancer patients","volume":"140","author":"Cheng","year":"2017","journal-title":"Int J Cancer"},{"key":"10.1016\/j.esmoop.2026.108349_bib41","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/1869304","article-title":"The role of BRCA2 mutation status as diagnostic, predictive, and prognosis biomarker for pancreatic cancer","volume":"2016","author":"Martinez-Useros","year":"2016","journal-title":"Biomed Res Int"},{"issue":"9","key":"10.1016\/j.esmoop.2026.108349_bib105","doi-asserted-by":"crossref","first-page":"S576","DOI":"10.1016\/j.jtho.2022.07.1044","article-title":"EP16.02-013 Retrospective analysis of BRCA1\/2 alterations in advanced NSCLC using an amplicon-based NGS liquid biopsy assay","volume":"17","author":"Poh","year":"2022","journal-title":"J Thorac Oncol"},{"issue":"24","key":"10.1016\/j.esmoop.2026.108349_bib28","doi-asserted-by":"crossref","first-page":"5207","DOI":"10.1158\/1078-0432.CCR-23-1467","article-title":"The clinical implications of reversions in patients with advanced pancreatic cancer and pathogenic variants in BRCA1, BRCA2, or PALB2 after progression on rucaparib","volume":"29","author":"Brown","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.esmoop.2026.108349_bib43","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1186\/s12943-025-02355-1","article-title":"Clinical approaches to overcome PARP inhibitor resistance","volume":"24","author":"Zou","year":"2025","journal-title":"Mol Cancer"},{"issue":"10","key":"10.1016\/j.esmoop.2026.108349_bib44","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1158\/2159-8290.CD-19-1485","article-title":"Clinical BRCA1\/2 reversion analysis identifies hotspot mutations and predicted neoantigens associated with therapy resistance","volume":"10","author":"Pettitt","year":"2020","journal-title":"Cancer Discov"},{"issue":"1","key":"10.1016\/j.esmoop.2026.108349_bib46","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1186\/s12943-024-02048-1","article-title":"BRCA1 secondary splice-site mutations drive exon-skipping and PARP inhibitor resistance","volume":"23","author":"Nesic","year":"2024","journal-title":"Mol Cancer"},{"key":"10.1016\/j.esmoop.2026.108349_bib47","doi-asserted-by":"crossref","DOI":"10.1016\/j.dnarep.2025.103830","article-title":"PARP inhibitors in ovarian cancer: mechanisms of resistance and implications to therapy","volume":"149","author":"Kulkarni","year":"2025","journal-title":"DNA Repair (Amst)"},{"issue":"8","key":"10.1016\/j.esmoop.2026.108349_bib48","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1056\/NEJMoa2214676","article-title":"Rucaparib or physician\u2019s choice in metastatic prostate cancer","volume":"388","author":"Fizazi","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.esmoop.2026.108349_bib49","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.lungcan.2022.08.004","article-title":"The evolving role of liquid biopsy in lung cancer","volume":"172","author":"Malapelle","year":"2022","journal-title":"Lung Cancer"},{"issue":"3","key":"10.1016\/j.esmoop.2026.108349_bib50","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100164","article-title":"The molecular profiling of solid tumors by liquid biopsy: a position paper of the AIOM-SIAPEC-IAP-SIBioC-SIC-SIF Italian scientific societies","volume":"6","author":"Russo","year":"2021","journal-title":"ESMO Open"},{"issue":"1","key":"10.1016\/j.esmoop.2026.108349_bib51","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1186\/s13045-022-01351-y","article-title":"Liquid biopsy: current technology and clinical applications","volume":"15","author":"Nikanjam","year":"2022","journal-title":"J Hematol Oncol"},{"issue":"3","key":"10.1016\/j.esmoop.2026.108349_bib52","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1007\/s10549-019-05425-3","article-title":"Multiplex ddPCR assay for screening copy number variations in BRCA1 gene","volume":"178","author":"Oscorbin","year":"2019","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"10.1016\/j.esmoop.2026.108349_bib53","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/cjp2.146","article-title":"Longitudinal analysis of a secondary BRCA2 mutation using digital droplet PCR","volume":"6","author":"Khalique","year":"2020","journal-title":"J Pathol Clin Res"},{"issue":"3","key":"10.1016\/j.esmoop.2026.108349_bib54","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1007\/s10549-017-4357-7","article-title":"Detection of BRCA1 gross rearrangements by droplet digital PCR","volume":"165","author":"Preobrazhenskaya","year":"2017","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.esmoop.2026.108349_bib55","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.cca.2020.12.001","article-title":"Droplet digital PCR for large genomic rearrangements detection: a promising strategy in tissue BRCA1 testing","volume":"513","author":"De Paolis","year":"2021","journal-title":"Clin Chim Acta"},{"issue":"8","key":"10.1016\/j.esmoop.2026.108349_bib56","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1016\/j.jmoldx.2020.04.213","article-title":"Next-generation sequencing in high-sensitive detection of mutations in tumors: challenges, advances, and applications","volume":"22","author":"Singh","year":"2020","journal-title":"J Mol Diagn"},{"key":"10.1016\/j.esmoop.2026.108349_bib57","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2021.103525","article-title":"Next generation diagnostic algorithm in non-small cell lung cancer predictive molecular pathology: the KWAY Italian multicenter cost evaluation study","volume":"169","author":"Pisapia","year":"2022","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.esmoop.2026.108349_bib58","doi-asserted-by":"crossref","first-page":"464","DOI":"10.18632\/oncotarget.28213","article-title":"Sequencing of BRCA1\/2-alterations using NGS-based technology: annotation as a challenge","volume":"13","author":"Ebner","year":"2022","journal-title":"Oncotarget"},{"issue":"3","key":"10.1016\/j.esmoop.2026.108349_bib59","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.euo.2023.08.004","article-title":"Practical guidance on establishing a molecular testing pathway for alterations in homologous recombination repair genes in clinical practice for patients with metastatic prostate cancer","volume":"7","author":"Schostak","year":"2024","journal-title":"Eur Urol Oncol"},{"issue":"3","key":"10.1016\/j.esmoop.2026.108349_bib60","doi-asserted-by":"crossref","first-page":"R157","DOI":"10.1530\/ERC-15-0369","article-title":"Methylated circulating tumor DNA in blood: power in cancer prognosis and response","volume":"23","author":"Warton","year":"2016","journal-title":"Endocr Relat Cancer"},{"issue":"1","key":"10.1016\/j.esmoop.2026.108349_bib61","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.cell.2013.03.008","article-title":"Interplay between the cancer genome and epigenome","volume":"153","author":"Shen","year":"2013","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.esmoop.2026.108349_bib96","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1186\/s13148-024-01787-8","article-title":"BRCA1 & BRCA2 methylation as a prognostic and predictive biomarker in cancer: implementation in liquid biopsy in the era of precision medicine","volume":"16","author":"Panagopoulou","year":"2024","journal-title":"Clin Epigenetics"},{"issue":"10","key":"10.1016\/j.esmoop.2026.108349_bib62","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1038\/s41587-022-01652-0","article-title":"Simultaneous sequencing of genetic and epigenetic bases in DNA","volume":"41","author":"F\u00fcllgrabe","year":"2023","journal-title":"Nat Biotechnol"},{"issue":"10","key":"10.1016\/j.esmoop.2026.108349_bib63","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000019345","article-title":"The association between the methylation frequency of BRCA1\/2 gene promoter and occurrence and prognosis of breast carcinoma: a meta-analysis","volume":"99","author":"Li","year":"2020","journal-title":"Medicine (Baltimore)"},{"issue":"6","key":"10.1016\/j.esmoop.2026.108349_bib64","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1038\/s41551-021-00746-5","article-title":"Ultrasensitive detection of circulating tumour DNA via deep methylation sequencing aided by machine learning","volume":"5","author":"Liang","year":"2021","journal-title":"Nat Biomed Eng"},{"key":"10.1016\/j.esmoop.2026.108349_bib65","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2022.104222","article-title":"Plasma cfDNA methylation markers for the detection and prognosis of ovarian cancer","volume":"83","author":"Liang","year":"2022","journal-title":"EBioMedicine"},{"issue":"1","key":"10.1016\/j.esmoop.2026.108349_bib66","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/s41391-019-0153-2","article-title":"Role of the DNA damage response in prostate cancer formation, progression and treatment","volume":"23","author":"Zhang","year":"2020","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"5","key":"10.1016\/j.esmoop.2026.108349_bib67","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/j.cell.2015.05.001","article-title":"Integrative clinical genomics of advanced prostate cancer","volume":"161","author":"Robinson","year":"2015","journal-title":"Cell"},{"issue":"24","key":"10.1016\/j.esmoop.2026.108349_bib68","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1056\/NEJMoa2022485","article-title":"Survival with olaparib in metastatic castration-resistant prostate cancer","volume":"383","author":"Hussain","year":"2020","journal-title":"N Engl J Med"},{"issue":"18","key":"10.1016\/j.esmoop.2026.108349_bib69","doi-asserted-by":"crossref","first-page":"3339","DOI":"10.1200\/JCO.22.01649","article-title":"Niraparib and abiraterone acetate for metastatic castration-resistant prostate cancer","volume":"41","author":"Chi","year":"2023","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.esmoop.2026.108349_bib70","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200043","article-title":"Abiraterone and olaparib for metastatic castration-resistant prostate cancer","volume":"1","author":"Clarke","year":"2022","journal-title":"NEJM Evid"},{"issue":"3","key":"10.1016\/j.esmoop.2026.108349_bib71","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.eururo.2023.05.021","article-title":"Rucaparib for the treatment of metastatic castration-resistant prostate cancer associated with a DNA damage repair gene alteration: final results from the phase 2 TRITON2 study","volume":"84","author":"Abida","year":"2023","journal-title":"Eur Urol"},{"issue":"3","key":"10.1016\/j.esmoop.2026.108349_bib72","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/S1470-2045(21)00757-9","article-title":"Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial","volume":"23","author":"Smith","year":"2022","journal-title":"Lancet Oncol"},{"issue":"9","key":"10.1016\/j.esmoop.2026.108349_bib73","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1016\/S1470-2045(21)00376-4","article-title":"Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trial","volume":"22","author":"de Bono","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.esmoop.2026.108349_bib113","doi-asserted-by":"crossref","DOI":"10.1002\/ijc.70679","article-title":"Global Real-World Outcomes of Olaparib in Metastatic Castration-Resistant Prostate Cancer Patients With Homologous Recombination Repair Alterations","author":"Incorvaia","year":"2026","journal-title":"Int J Cancer"},{"issue":"12","key":"10.1016\/j.esmoop.2026.108349_bib74","doi-asserted-by":"crossref","DOI":"10.1093\/oncolo\/oyaf395","article-title":"Homologous recombination repair genetic testing variables and diagnostic paths for prostate cancer patients: a multicenter cohort study","volume":"30","author":"Incorvaia","year":"2025","journal-title":"Oncologist"},{"issue":"8","key":"10.1016\/j.esmoop.2026.108349_bib75","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1158\/1078-0432.CCR-21-3940","article-title":"Tumor genomic testing for >4,000 men with metastatic castration-resistant prostate cancer in the phase III trial PROfound (Olaparib)","volume":"28","author":"Hussain","year":"2022","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.esmoop.2026.108349_bib76","article-title":"Toward informed selection and interpretation of clinical genomic tests in prostate cancer","volume":"8","author":"Vandekerkhove","year":"2024","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.esmoop.2026.108349_bib77","article-title":"Real-world performance of a comprehensive genomic profiling test optimized for small tumor samples","volume":"5","author":"Tomlins","year":"2021","journal-title":"JCO Precis Oncol"},{"issue":"8","key":"10.1016\/j.esmoop.2026.108349_bib78","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1038\/s41416-022-01881-9","article-title":"Blood-based liquid biopsies for prostate cancer: clinical opportunities and challenges","volume":"127","author":"Trujillo","year":"2022","journal-title":"Br J Cancer"},{"issue":"1","key":"10.1016\/j.esmoop.2026.108349_bib79","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1186\/s12885-025-13521-5","article-title":"Integrating BRCA testing into routine prostate cancer care: a multidisciplinary approach by SIUrO and other Italian scientific societies","volume":"25","author":"Mammone","year":"2025","journal-title":"BMC Cancer"},{"key":"10.1016\/j.esmoop.2026.108349_bib80","article-title":"Liquid biopsy in oncology: results of a Delphi consensus study endorsed by the AIOM-SIAPEC\/IAP-SIBioC-SIF Italian scientific societies","volume":"11","author":"Gristina","year":"2025","journal-title":"J Liq Biopsy"},{"issue":"1","key":"10.1016\/j.esmoop.2026.108349_bib81","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1038\/s41467-024-45475-w","article-title":"Prediction of plasma ctDNA fraction and prognostic implications of liquid biopsy in advanced prostate cancer","volume":"15","author":"Fonseca","year":"2024","journal-title":"Nat Commun"},{"issue":"11","key":"10.1016\/j.esmoop.2026.108349_bib82","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/j.trecan.2021.06.001","article-title":"Technical and biological constraints on ctDNA-based genotyping","volume":"7","author":"Herberts","year":"2021","journal-title":"Trends Cancer"},{"issue":"10295","key":"10.1016\/j.esmoop.2026.108349_bib83","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S0140-6736(21)00580-8","article-title":"Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trial","volume":"398","author":"Sweeney","year":"2021","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.esmoop.2026.108349_bib84","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/j.annonc.2021.03.196","article-title":"Plasma tumor gene conversions after one cycle abiraterone acetate for metastatic castration-resistant prostate cancer: a biomarker analysis of a multicenter international trial","volume":"32","author":"Jayaram","year":"2021","journal-title":"Ann Oncol"},{"issue":"11","key":"10.1016\/j.esmoop.2026.108349_bib85","doi-asserted-by":"crossref","first-page":"3094","DOI":"10.1158\/1078-0432.CCR-20-4805","article-title":"Genomic analysis of circulating tumor DNA in 3,334 patients with advanced prostate cancer identifies targetable BRCA alterations and AR resistance mechanisms","volume":"27","author":"Tukachinsky","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.esmoop.2026.108349_bib86","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.euf.2024.02.007","article-title":"Feasibility of next-generation sequencing of liquid biopsy (circulating tumor DNA) samples and tumor tissue from patients with metastatic prostate cancer in a real-world clinical setting in Germany","volume":"10","author":"Mandel","year":"2024","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.esmoop.2026.108349_bib87","doi-asserted-by":"crossref","first-page":"6275","DOI":"10.2147\/CMAR.S206817","article-title":"Frequency of germline mutations in BRCA1 and BRCA2 in ovarian cancer patients and their effect on treatment outcome","volume":"11","author":"Ashour","year":"2019","journal-title":"Cancer Manag Res"},{"key":"10.1016\/j.esmoop.2026.108349_bib88","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.critrevonc.2019.05.012","article-title":"Recommendations for the implementation of BRCA testing in ovarian cancer patients and their relatives","volume":"140","author":"Gori","year":"2019","journal-title":"Crit Rev Oncol Hematol"},{"issue":"4","key":"10.1016\/j.esmoop.2026.108349_bib89","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.104533","article-title":"Benefit from maintenance with PARP inhibitor in newly diagnosed ovarian cancer according to BRCA1\/2 mutation type and site: a multicenter real-world study","volume":"10","author":"Marchetti","year":"2025","journal-title":"ESMO Open"},{"issue":"2","key":"10.1016\/j.esmoop.2026.108349_bib90","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.104076","article-title":"BRCA functional domains associated with high risk of multiple primary tumors and domain-related sensitivity to olaparib: the Prometheus study","volume":"10","author":"Incorvaia","year":"2025","journal-title":"ESMO Open"},{"issue":"7","key":"10.1016\/j.esmoop.2026.108349_bib91","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1136\/jcp-2023-208852","article-title":"In-house homologous recombination deficiency testing in ovarian cancer: a multi-institutional Italian pilot study","volume":"77","author":"Pepe","year":"2024","journal-title":"J Clin Pathol"},{"issue":"suppl 22","key":"10.1016\/j.esmoop.2026.108349_bib92","article-title":"Abstract GMM-048: ctDNA response to the PARP inhibitor rucaparib predicts progression-free survival and best overall response on the ARIEL2 trial","volume":"25","author":"Piskorz","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.esmoop.2026.108349_bib93","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S1470-2045(16)30559-9","article-title":"Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 part 1): an international, multicentre, open-label, phase 2 trial","volume":"18","author":"Swisher","year":"2017","journal-title":"Lancet Oncol"},{"issue":"12","key":"10.1016\/j.esmoop.2026.108349_bib94","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1200\/JCO.2016.70.4627","article-title":"Reversion of BRCA1\/2 germline mutations detected in circulating tumor DNA from patients with high-grade serous ovarian cancer","volume":"35","author":"Christie","year":"2017","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2026.108349_bib95","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1186\/s12943-023-01864-1","article-title":"Homologous recombination deficiency (HRD) testing on cell-free tumor DNA from peritoneal fluid","volume":"22","author":"Roussel-Simonin","year":"2023","journal-title":"Mol Cancer"},{"issue":"13","key":"10.1016\/j.esmoop.2026.108349_bib97","doi-asserted-by":"crossref","first-page":"3239","DOI":"10.1158\/1078-0432.CCR-20-0418","article-title":"Genomic methods identify homologous recombination deficiency in pancreas adenocarcinoma and optimize treatment selection","volume":"26","author":"Park","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.esmoop.2026.108349_bib98","doi-asserted-by":"crossref","DOI":"10.1177\/17588359221083050","article-title":"Platinum-based chemotherapy for pancreatic cancer: impact of mutations in the homologous recombination repair and Fanconi anemia genes","volume":"14","author":"Emelyanova","year":"2022","journal-title":"Ther Adv Med Oncol"},{"issue":"suppl 2","key":"10.1016\/j.esmoop.2026.108349_bib99","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1200\/JCO.2026.44.2_suppl.769","article-title":"Survival and treatment trends in BRCA-mutated metastatic pancreatic adenocarcinoma","volume":"44","author":"Haw","year":"2026","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2026.108349_bib101","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1158\/1078-0432.CCR-21-3577","article-title":"Olaparib efficacy in patients with metastatic castration-resistant prostate cancer and BRCA1, BRCA2, or ATM alterations identified by testing circulating tumor DNA","volume":"29","author":"Matsubara","year":"2023","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.esmoop.2026.108349_bib102","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2022.07.1502","article-title":"1370P Detection of mutations in homologous recombination repair (HRR) genes in tumour tissue (TT) and circulating tumour DNA (ctDNA) from patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC) in the phase III PROpel trial","volume":"33","author":"Armstrong","year":"2022","journal-title":"Ann Oncol"},{"issue":"9","key":"10.1016\/j.esmoop.2026.108349_bib103","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/j.annonc.2023.06.009","article-title":"Niraparib plus abiraterone acetate with prednisone in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: second interim analysis of the randomized phase III MAGNITUDE trial","volume":"34","author":"Chi","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2026.108349_bib104","article-title":"72P Treatments response in non-small cell lung cancer patients according to BRCA status on liquid biopsy: a retrospective analysis","volume":"16","author":"Provenzano","year":"2022","journal-title":"Immuno-Oncol Technol"},{"key":"10.1016\/j.esmoop.2026.108349_bib106","doi-asserted-by":"crossref","first-page":"v31","DOI":"10.1093\/annonc\/mdz239.019","volume":"30","author":"Kawamoto","year":"2019","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.esmoop.2026.108349_bib107","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1038\/s41417-023-00721-z","article-title":"Detection of (pre)cancerous colorectal lesions in Lynch syndrome patients by microsatellite instability liquid biopsy","volume":"31","author":"Boeri","year":"2024","journal-title":"Cancer Gene Ther"},{"key":"10.1016\/j.esmoop.2026.108349_bib42","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/9873954","article-title":"Cancer surveillance in healthy carriers of germline pathogenic variants in BRCA1\/2: a review of secondary prevention guidelines","volume":"2020","author":"Dullens","year":"2020","journal-title":"J Oncol"},{"issue":"12","key":"10.1016\/j.esmoop.2026.108349_bib108","doi-asserted-by":"crossref","first-page":"477","DOI":"10.3390\/cancers10120477","article-title":"Screening BRCA1 and BRCA2 mutation carriers for breast cancer","volume":"10","author":"Warner","year":"2018","journal-title":"Cancers (Basel)"},{"issue":"6538","key":"10.1016\/j.esmoop.2026.108349_bib109","doi-asserted-by":"crossref","DOI":"10.1126\/science.aaw3616","article-title":"Epigenetics, fragmentomics, and topology of cell-free DNA in liquid biopsies","volume":"372","author":"Lo","year":"2021","journal-title":"Science"},{"issue":"10409","key":"10.1016\/j.esmoop.2026.108349_bib110","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1016\/S0140-6736(23)01700-2","article-title":"Blood-based tests for multicancer early detection (PATHFINDER): a prospective cohort study","volume":"402","author":"Schrag","year":"2023","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.esmoop.2026.108349_bib111","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1016\/j.annonc.2021.05.806","article-title":"Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set","volume":"32","author":"Klein","year":"2021","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2026.108349_bib112","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1158\/2159-8290.CD-24-0393","article-title":"Early detection of ovarian cancer using cell-free DNA fragmentomes and protein biomarkers","volume":"15","author":"Medina","year":"2025","journal-title":"Cancer Discov"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S205970292602291X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S205970292602291X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T23:40:40Z","timestamp":1792712440000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S205970292602291X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":112,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S205970292602291X"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2026.108349","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Liquid biopsy: a new window on the BRCA genes","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2026.108349","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"108349"}}